EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-world survival outcomes of sequential treatment strategy for newly diagnosed advanced high-grade serous ovarian cancer

Eun Taeg Kim, Sun Young Ma, Tae Kyoung Kang, Tae Hwa Lee, Dong Hwi Kim, Won Gyu Kim

Kosin Medical Journal · 31.03.2026 · 41 (1) · 37-45

DOI: 10.7180/kmj.25.130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kosin Medical Journal, erschienen am 31.03.2026. Verfasst von Eun Taeg Kim und 5 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kosin University College of Medicine.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Various strategies are being explored to improve outcomes in advanced ovarian cancer. This study evaluated the survival outcomes of a sequential treatment strategy comprising dose-dense weekly chemotherapy, selective adjuvant radiotherapy, and poly(ADP-ribose) polymerase (PARP) inhibitor maintenance following primary debulking surgery.

Methods

We retrospectively reviewed 12 patients with newly diagnosed advanced high-grade serous ovarian cancer (HGSOC) who underwent a sequential treatment strategy (debulking surgery followed by dose-dense chemotherapy, selective adjuvant radiotherapy, and PARP inhibitor maintenance) at Kosin University Gospel Hospital between December 2019 and March 2023. Survival outcomes were analyzed using the Kaplan-Meier method, and treatment-related adverse effects were evaluated.

Results

All 12 patients achieved complete remission after the sequential treatment strategy. At the cutoff date (June 20, 2025), all patients were alive, with a median follow-up duration of 48.1 months (range, 28.7–66.5 months). The median progression-free survival (PFS) was 43.8 months. Acute toxicities, including bone marrow suppression and alopecia, were transient and manageable. Peripheral neuropathy and extremity edema were observed as persistent late toxicities.

Conclusions

This study highlights promising outcomes with a multimodal sequential treatment strategy in newly diagnosed advanced HGSOC. All patients remained alive at the time of analysis, and the median PFS reached 43.8 months, suggesting a potential benefit of this sequential approach compared with conventional treatment strategies. Prospective studies are warranted to validate these findings.

Förderung

  • Kosin University College of Medicine

Zitieren

APA

Kim, E. T., Ma, S. Y., Kang, T. K., Lee, T. H., Kim, D. H., & Kim, W. G. (2026). Real-world survival outcomes of sequential treatment strategy for newly diagnosed advanced high-grade serous ovarian cancer. Kosin Medical Journal, 41(1), 37-45. https://doi.org/10.7180/kmj.25.130

Vancouver

Kim ET, Ma SY, Kang TK, Lee TH, Kim DH, Kim WG. Real-world survival outcomes of sequential treatment strategy for newly diagnosed advanced high-grade serous ovarian cancer. Kosin Medical Journal. 2026;41(1):37-45. doi:10.7180/kmj.25.130

BibTeX
@article{Kim2026,
  author = {Kim, Eun Taeg and Ma, Sun Young and Kang, Tae Kyoung and Lee, Tae Hwa and Kim, Dong Hwi and Kim, Won Gyu},
  title = {Real-world survival outcomes of sequential treatment strategy for newly diagnosed advanced high-grade serous ovarian cancer},
  journal = {Kosin Medical Journal},
  year = {2026},
  volume = {41},
  number = {1},
  pages = {37--45},
  doi = {10.7180/kmj.25.130}
}
Kostenlos starten →